Not logged in Share Save
Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma Choueiri, Toni K.; Donahue, Amber C.; Braun, David A.; Rini, Brian I.; Powles, Thomas; Haanen, John B. A. G.; Larkin, James; Mu, Xinmeng Jasmine; Pu, Jie; Teresi, Rosemary E.; di Pietro, Alessandra; Robbins, Paul B.; Motzer, Robert J. Share Save
Case Studies for Overcoming Challenges in Using Big Data in Cancer Sweeney, Shawn M.; Hamadeh, Hisham K.; Abrams, Natalie; Adam, Stacey J.; Brenner, Sara; Connors, Dana E.; Davis, Gerard J.; Fiore, Louis D.; Gawel, Susan H.; Grossman, Robert L.; Hanlon, Sean E.; Hsu, Karl; Kelloff, Gary J.; Kirsch, Ilan R.; Louv, Bill; McGraw, Deven; Meng, Frank; Milgram, Daniel; Miller, Robert S.; Morgan, Emily; Mukundam, Lata; O'Brien, Thoma; Robbins, Paul; Rubin, Eric H.; Rubinstein, Wendy S.; Salmi, Liz; Schaller, Teilo H.; Shi, George; Sigman, Caroline C.; Srivastava, Sudhir Share Save
Challenges to Using Big Data in Cancer Sweeney, Shawn M.; Hamadeh, Hisham K.; Abrams, Natalie; Adam, Stacey J.; Brenner, Sara; Connors, Dana E.; Davis, Gerard J.; Fiore, Louis; Gawel, Susan H.; Grossman, Robert L.; Hanlon, Sean E.; Hsu, Karl; Kelloff, Gary J.; Kirsch, Ilan R.; Louv, Bill; McGraw, Deven; Meng, Frank; Milgram, Daniel; Miller, Robert S.; Morgan, Emily; Mukundan, Lata; O'Brien, Thomas; Robbins, Paul; Rubin, Eric H.; Rubinstein, Wendy S.; Salmi, Liz; Schaller, Teilo; Shi, George; Sigman, Caroline C.; Srivastava, Sudhir Share Save
Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial Choueiri, T. K.; Larkin, J.; Pal, S.; Motzer, R. J.; Rini, B., I; Venugopal, B.; Alekseev, B.; Miyake, H.; Gravis, G.; Bilen, M. A.; Hariharan, S.; Chudnovsky, A.; Ching, K. A.; Mu, X. J.; Mariani, M.; Robbins, P. B.; Huang, B.; di Pietro, A.; Albiges, L. Share Save
Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial Kudo, Masatoshi; Motomura, Kenta; Wada, Yoshiyuki; Inaba, Yoshitaka; Sakamoto, Yasunari; Kurosaki, Masayuki; Umeyama, Yoshiko; Kamei, Yoichi; Yoshimitsu, Junichiro; Fujii, Yosuke; Aizawa, Mana; Robbins, Paul B.; Furuse, Junji Share Save
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial Motzer, Robert J.; Robbins, Paul B.; Powles, Thomas; Albiges, Laurence; Haanen, John B.; Larkin, James; Mu, Xinmeng Jasmine; Ching, Keith A.; Uemura, Motohide; Pal, Sumanta K.; Alekseev, Boris; Gravis, Gwenaelle; Campbell, Matthew T.; Penkov, Konstantin; Lee, Jae Lyun; Hariharan, Subramanian; Wang, Xiao; Zhang, Weidong; Wang, Jing; Chudnovsky, Aleksander; di Pietro, Alessandra; Donahue, Amber C.; Choueiri, Toni K. Share Save
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma Motzer, Robert J.; Penkov, Konstantin; Haanen, John; Rini, Brian; Albiges, Laurence; Campbell, Matthew T.; Venugopal, Balaji; Kollmannsberger, Christian; Negrier, Sylvie; Uemura, Motohide; Lee, Jae L.; Vasiliev, Aleksandr; Miller, Wilson H., Jr.; Gurney, Howard; Schmidinger, Manuela; Larkin, James; Atkins, Michael B.; Bedke, Jens; Alekseev, Boris; Wang, Jing; Mariani, Mariangela; Robbins, Paul B.; Chudnovsky, Aleksander; Fowst, Camilla; Hariharan, Subramanian; Huang, Bo; di Pietro, Alessandra; Choueiri, Toni K. Share Save
Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort Segal, Neil H.; Ou, Sai-Hong, I; Balmanoukian, Ani; Fury, Matthew G.; Massarelli, Etiuinia; Brahmer, Julie R.; Weiss, Jared; Schoffski, Patrick; Antonia, Scott J.; Massard, Christophe; Zandberg, Dan P.; Khleif, Samir N.; Xiao, Feng; Rebelatto, Marlon C.; Steele, Keith E.; Robbins, Paul B.; Angra, Natasha; Song, Xuyang; Abdullah, Shaad; Butler, Marcus Share Save
High tumoral IFNγ mRNA, PD-L1 protein, and combined IFNγ mRNA/PD-L1 protein expression associates with response to durvalumab (anti-PD-L1) monotherapy in NSCLC patients Higgs, B. W.; Robbins, P. B.; Blake-Haskins, J. A.; Zhu, W.; Morehouse, C.; Brohawn, P. Z.; Rebelatto, M. C.; Yao, Y.; Jin, X.; Shi, L.; Ranade, K. Share Save
Population pharmacokinetics of MEDI4736, a fully human anti-programmed death ligand 1 (PD-L1) monoclonal antibody, in patients with advanced solid tumors Song, X.; Pak, M.; Chavez, C.; Liang, M.; Lu, H.; Blake-Haskins, J. A.; Robbins, P. B.; Jin, X.; Gupta, A.; Roskos, L.; Narwal, R. Share Save
A Phase 1b study to evaluate the safety and antitumor activity of MEDI4736 in combination with tremelimumab in patients with advanced NSCLC Goldberg, S. B.; Balmanoukian, A.; Chaft, J.; Rizvi, N.; Sanborn, R. E.; Rebelatto, M. C.; Narwal, R.; Robbins, P. B.; Gu, Y.; Karakunnel, J. J.; Antonia, S. Share Save
Pharmacokinetics of Tremelimumab, a fully human anti-CTLA-4 monoclonal antibody, in subjects with unresectable malignant mesothelioma Calabro, Luana; Narwal, Rajesh; Robbins, Paul B.; Pietro, Alessandra D.; Cutaia, Ornella; Fonsatti, Ester; Annesi, Diego; Fazio, Carolina; Ibrahim, Ramy; Maio, Michele Share Save
Share Save
Share Save
Share Save
Share Save
Share Save
Share Save
Share Save
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Not logged in.png){kind=icon}
